Naturally occurring primary canine lung cancers are aggressive malignancies that are increasingly common in pet dogs. They share clinicopathologic features with human lung cancers in never-smokers, but their genetic underpinnings are unknown. Through multi-platform sequencing of 88 primary canine lung tumors or cell lines, we discovered somatic, coding HER2 (ERRB2) point mutations in 38% of canine pulmonary adenocarcinomas (cPAC, 28/74), but none in adenosquamous (cPASC, 0/11) or squamous cell (cPSCC, 0/3) carcinomas. In cPASC, PTEN was the most frequently mutated gene (18%) while one case each bore likely pathogenic HRAS, KRAS, EGFR, MET, TP53, or VHL somatic mutations. In cPSCC, no recurrently mutated genes were identified, but individual somatic coding mutations were found in BRAF and PTPN11. In cPAC, we also identified recurrent somatic mutation of TP53 (13.5%), SMAD4 (5.4%), PTEN (4.1%), and VHL (2.7%). cPACs assessed by exome sequencing displayed a low somatic mutation burden (median 64 point mutations, 19 focal copy number variants, and 1 translocation). The majority (93%) of HER2 mutations were hotspot V659E transmembrane domain (TMD) mutations comparable to activating mutations at this same site in human cancer.
Five-year overall survival is estimated at 23%, but outcomes are dependent on molecular subtype and treatment regimen. For example, EGFR inhibitors can improve outcomes in EGFR-mutant lung cancers, however 85% of never-smoker lung AC and SCC cases are EGFR wild-type (WT) in the United States. Clinical trials of immune checkpoint inhibitors have recently shown improved outcomes for human lung cancers, but analysis of large phase II immunotherapy trials suggests that benefits are limited in low-mutation-burden (≤ 10 mutations/Mb) cases such as those found in smokers 5 . A need exists for improved biologic understanding and development of new models to fuel translational research in never-smoker lung cancer.
Lung cancer in pet dogs has limited standard of care beyond surgery and little is known of its molecular underpinnings 1 . Primary lung tumors typically arise in older dogs (11 years) and resemble human NSCLC histotypes including canine pulmonary adenocarcinoma (cPAC), adenosquamous carcinoma (cPASC), and squamous cell carcinoma (cPSCC). These subtypes collectively represent 13-15% of primary lung tumors 6, 7 . Patients are often diagnosed late with lesions incidentally discovered during routine geriatric evaluation or due to nonspecific symptoms including dyspnea (6% to 24%) and cough (52% to 93%) that do not manifest until the tumor is more than 3 cm. These tumors can be diagnostically challenging. Rates at which ultrasound or CT-guided fine needle aspirates of the pulmonary mass provide cytologic diagnosis range from 38% to 90% of cases, varying broadly based on tumor accessibility and aspirate quality. At diagnosis, 71% of malignant canine lung tumors show signs of invasion and 23% show distant metastasis. Partial or complete lung lobectomy is standard of care, dependent on extent of disease spread. Median survival is 345 days for localized disease without nodal involvement where surgical remission can be achieved, but only 60 days when nodes are involved. Responses to cytotoxic chemotherapy (cisplatin, vindesine, doxorubicin, and mitoxantrone) in the setting of disseminated disease are limited. Targeted small molecules and immune checkpoint inhibitors have not been extensively studied in part because the molecular underpinnings of canine lung cancer remain largely unknown. In naturally occurring canine NSCLC, while comprehensive genomic profiling has been limited, KRAS hotspot mutation prevalence estimates from targeted studies have varied from 0-25% [7] [8] [9] . We have previously shown that EGFR mutation, overexpression, or phosphorylation is rare in cPAC compared to matched non-affected chemotherapy-naive lung tissue whereas significant overexpression and/or phosphorylation of PDGFRα, ALK, and HER2 are present 10 . We now describe for the first time the detailed genetic underpinnings of primary canine lung cancers through multi-platform nextgeneration sequencing of 88 cases.
RESULTS

The genomic landscape of naturally occurring primary canine lung cancer
In order to map the genomic landscape of primary canine lung cancer we undertook multiplatform next-generation sequencing of 88 NSCLC cases including 77 tumor/normal matched pairs and 11 cell lines ( Table 1 ). The cohort included 74 cPAC, 11 cPASC, and 3 cPSCC.
Labrador retrievers represented the most commonly affected pure breed dog (21%) with mixed breeds (25%) and multiple other single pure breeds. The predominant cPAC subtype was papillary adenocarcinoma (62%). The cohort was gender-balanced (52% females) and primarily neutered/spayed (92%) with a median age at diagnosis of 11 years. Smoking status in the pet's household was not available. Extended clinical annotation is shown in Table S1 and Figure S1.
To identify somatic point mutations, copy number changes, and translocations, we first sequenced the coding genomic regions of five cPAC tumors and matching normal samples using a custom Agilent SureSelect canine exome capture kit comprising 982,789 probes covering 19,459 genes. Tumors were sequenced to mean target coverage of 298X with 99% of target bases covered ≥ 40X (Table S2 ). Constitutional DNA samples were sequenced to mean target coverage of 263X with 99% of target bases covered ≥ 40X. A total of 648 high-confidence somatic SNVs (median 64, range 37-406), 165 focal CNVs (median 19, range 0-116), and 3 SVs (median 1, range 0-1) were identified (Tables S3-S5 and Figure 1A , 1B, and 1C). We identified non-recurrent, somatic SNVs in genes whose human orthologs have been implicated in human cancer according to COSMIC 11 Tiers 1 and 2 including nonsynonymous variants in BCLAF1, CD274, CDH10, CSMD3, FANCD2, FOXP1, KIT, MAML3, NOTCH2, PER1, PTPN13, SEPT9 and TP53 (Table S3 ). Large-scale recurrent single copy changes (whole chromosome or armlevel gains/losses) included canis familaris chromosome (CFA) 1 loss, CFA4 gain, CFA5 loss, CFA11 loss, CFA20 loss, CFA22 gain, CFA25 loss, CFA28 loss, and CFA35 loss ( Figure S2 ).
Focal CNVs containing COSMIC genes included deletions involving the tumor suppressor
CDKN2A/B locus (40% of cases) and PTEN (20%), as well as amplifications involving the oncogenes AKT1 (20%), KIT (20%), KDR (20%), and TERT (20%) ( Figure 1B and Table S4 ).
Of the three somatic SVs, only the WWTR1-ATP5F1 translocation impacted a COSMIC gene, WWTR1. The sole gene bearing recurrent nonsynonymous SNVs was HER2 (80%) with the missense mutation V659E occurring in three cases and the missense mutation K676E in a fourth case ( Figure 1D) . No HER2 amplifications were detected in these five tumors. We also assessed somatic point mutation signatures according to their trinucleotide context ( Figure S3) 12, 13 . The most common signature in these five cases was the age-associated COSMIC Signature 1A in 4/5 (80%) featuring frequent C>T substitutions at NpCpG trinucleotides. COSMIC Signature 2, associated with APOBEC cytidine deaminase activity, was also present in two cases, CCB050227 and OSU431895.
To identify somatic point mutations across a broader cohort of canine lung cancers, we used a custom canine cancer amplicon-based next generation sequencing panel to assess 281 coding regions (Table S6 ) of canine orthologs of 57 frequently mutated human cancer genes in 73 additional lung tumors (61 cPAC, 10 cPASC, 2 cPSCC), two previously exome-sequenced tumors with matched normal tissue, and 10 cell lines (8 cPAC, 1 cPASC, and 1 cPSCC). These cases were sequenced to an average depth of 3,383x (Table S7) (Table S8) . Two additional somatic mutations in HER2 including A664T and K676E were identified in single cases ( Figure 1D ).
Overall, recurrently mutated genes containing somatic potentially pathogenic SNVs included TP53 (12.5%), PTEN (5.7%), SMAD4 (4.5%), KRAS (4.5%), VHL (3.4%) and HRAS (2.3%).
Finally, based on both exome and amplicon sequencing, we evaluated germline SNPs to identify putatively pathogenic rare variants (i.e. those not previously identified in dogs based on review of presence in dbSNP 151 14 and/or ≥ 10% frequency in DogSD 15 ) in 81 genes previously reported to potentially be associated with susceptibility to lung cancer in humans 16 . Based on these criteria, we identified nine rare putatively pathogenic SNPs in five dogs in the genes CHRNA3, CYP1B1, DNAH11 and HER2 (Table S9) . Of these SNPs, the only variant with an equivalent in its human orthologous gene was DNAH11 R1460W corresponding to human DNAH11 R1444W (rs1035326227, MAF < 0.01%), but the human SNP has not been associated with a disease phenotype. The HER2 variants, both V1189I, occurred in two cases for which no somatic HER2 mutations were identified in tumor tissue. The human orthologous position, V1184, has not been shown to bear variation in human data. Though rare, the canine variant has been identified in 4% of cases in DogSD and, based on functional effect prediction (FATHMM), it is likely neutral. Finally, none of the genes bearing rare SNPs showed second somatic hits in tumor tissue and thus, overall, data to support their pathogenicity is limited.
We additionally performed matched tumor/normal amplicon sequencing to evaluate the genomic landscapes of 11 cPASC and 3 cPSCCs, subtypes which are under-studied entities in dogs and humans, especially in non-smokers ( Figure 1A and Table S8 ). In contrast with cPAC, no HER2 mutations were identified in these tumors. In cPASC, HRAS Q61L and KRAS Q61K each occurred in one case. Thus 18% of cases bore RAS hotspot mutations. PTEN stop gains additionally occurred in 2/11 (18%) of cases at high tumor allele frequencies and were exclusive with RAS mutations. Additional likely pathogenic somatic mutations also occurred in a single cancer gene in a single tumor each including EGFR A726T, MET M1269V, TP53 R147C, and VHL P97L. Finally, while no recurrent mutations were identified in the three cPSCCs, we identified one case with a somatic BRAF V588E and another bearing PTPN11 G503V.
HER2 is frequently mutated in canine pulmonary adenocarcinoma (cPAC)
HER2 was the most frequently mutated gene in our multi-platform next generation sequencing cohort, occurring exclusively in cPACs (27/74, 36 .5%) with two mutations occurring in a single patient ( Figure 1A) . We additionally identified a HER2 mutation in the cell line OSUK9PAPADRiley solely by Sanger sequencing of the codon 659 locus. We thus identified 29 total HER2 mutations overall ( Figure 1D) . In 24 cases, the HER2 variants were evaluated on at least two platforms including exome sequencing, amplicon sequencing, Sanger sequencing, and/or droplet digital PCR (ddPCR, Table S10 ). The HER2 variant tumor allele fraction (AF) median by amplicon sequencing was 21.3% (range 8.4 -51.9%). All low AF (< 20%) cases identified by amplicon sequencing were also validated by Sanger and/or ddPCR. Some low AF cases were not able to be visualized on Sanger traces, but were detectable by ddPCR. Notably, one cell line, OSUK9PAPADOscar, contained a low AF HER2 V659E variant (AFs of 15% by amplicon and 16% by ddPCR) during early short-term culture (passage 4) that was no longer detectable by Sanger sequencing or ddPCR in later passages (passage 15). Importantly, passage 15 was utilized for all functional studies described below and it was thus considered HER2 WT in this setting. Overall, V659E missense mutations located in the HER2 TMD occurred in 93.3% of HER2-mutant cases. Additional HER2 mutations included A664T (OSU419040) and K676E (CCB050354), which have not been previously described in orthologous human HER2 regions.
HER2 mutations co-occurred with mutations in TP53, SMAD4, VHL, PTEN, AKT1 or KDR.
TP53 was found in 3/27 (11%) of the 27 HER2-mutant tumors, although it was more commonly mutated in HER2 wild-type tumors. Three of the four SMAD4 mutations in this cohort were comutated in HER2-mutant tumors (11%). Additional co-occurring mutations included PTEN in 2/27 (11%) and VHL, AKT and KDR each co-mutated in a single HER2-mutant case.
HER2 mutations are detectable in canine plasma DNA
Cell-free tumor DNA (ctDNA) in plasma has been increasingly used for noninvasive genotyping in human cancer patients 17 . To develop a canine blood test that could rapidly identify dogs with HER2-mutant lung cancer, we investigated whether cPAC HER2 hotspot mutations are detectable in ctDNA. We evaluated plasma from 11 dogs, 5 with HER2-wild-type tumors and 6 with HER2 V659E tumors using droplet digital PCR (ddPCR) and custom primers targeting 57 bp surrounding codon 659 (Table S11 ). We analyzed wild-type tumor samples, plasma DNA from unrelated commercially available canine plasma samples and template-free controls to establish assay specificity (BioreclamationIVT #BGLPLEDTA-100-P-m). Using uniform gating for all experiments, we found 1/7 template-free samples showed 1 wild-type droplet and no samples showed any evidence of mutant DNA amplification. In wild-type tumor and plasma DNA samples, 2/8 samples showed 1 mutant droplet each. Based on these results, we required at least three mutant droplets to confidently detect HER2 V659E . We detected HER2 V659E in 6/6 positive control tumor DNA samples where we had previously identified V659E mutations using amplicon sequencing. In these samples, we observed a high correlation between allele fractions measured using amplicon sequencing and ddPCR (Pearson's r 0.976, p=0.0008). In 11 plasma samples from dogs with cPAC tested using ddPCR, median total cell-free DNA yield was 1.6 (range 0.3-10.0) ( Table S11 ). Requiring at least three mutant droplets to support mutation detection, the median limit of detection (LoD) for mutation allele fraction was calculated at 0.61% (range 0.10%-3.11%). HER2 V659E mutations were detected in 2/6 plasma samples from dogs with HER2 V659E -positive tumors at 1.9% and 2.3% allele fractions. Both ctDNA-positive cases had stage II cancer, consistent with low levels of ctDNA observed. HER2 V659E was not detected in any plasma samples from dogs with HER2 WT tumors, confirming assay specificity ( Figure 1E ).
HER2 expression in primary canine lung cancer
In human cancers, HER2 bears activating point mutations, focal amplifications or copy number gains, and overexpression (by qRT-PCR and/or immunohistochemistry). Amplification and overexpression are mutually exclusive with point mutations. To assess HER2 copy number gains and overexpression, HER2 copy number was first determined in the five exome-sequenced cases ( Figure S2 and Table S4 ). No large-scale CFA9 gains or focal HER2 amplifications were detected. However, these cases predominantly bore somatic putatively activating point mutations and might not be expected to contain concomitant gains. Therefore, we evaluated HER2 RNA and protein expression by qRT-PCR and IHC. RNA samples from 49 lung tumors within this cohort (9 HER2-mutant) alongside 14 normal lung tissue samples distal to tumor areas but from the same lung lobe were evaluated. Median HER2 expression fold-change relative to expression of the house-keeping gene HPRT in normal lung samples was 1.06 (range 0.28-4.11) and in tumors was 0.85 (range 0.07-4.50) ( Figure S4 ). No significant difference in relative HER2 expression was observed between tumor and normal or HER2-mutant and HER2 WT groups.
Additionally, in order to quantify HER2 protein expression in cPAC, digital image analysis was performed on eight tumors from FFPE. Three of the samples bore the HER2 V659E hotspot mutations, one bore HER2 A664T , and four were HER2 WT according to amplicon and Sanger sequencing. All cases were positive for HER2 staining with homogeneous and diffuse staining of tumor cell cytoplasm and cell membrane, but no staining in adjacent stroma or vasculature ( Figure S5) . Positive staining was observed in bronchial epithelium of the adjacent non-affected lung in all cases. Consistent with absence of observed HER2 amplifications, no significant differences (mean ± SEM) were detected in the tumor positivity percentage for HER2 (47±5.4 and 35±5.1) between the WT and HER2-mutant groups, respectively. No significant differences in HER2 staining were present for percent minimum (51±2.9 WT vs. 55±5.1, HER2 mutations) or percent maximum (97±0.31 WT vs. 96±0.47 HER2 mutations) stain intensity (Table S12) .
Overall, most tumors showed moderate expression of HER2 based on qRT-PCR and IHC with some variability, but levels were typically consistent with those seen in normal tissue and did not vary based on HER2 mutation status.
HER2 is constitutively active in HER2 V659E cPAC cell lines
In human cancers, HER2 V659E mutations increase HER2 autophosphorylation, EGFR phosphorylation, and activation of phosphatidyl-inositol-3-kinase (PI3K), and mitogen-activatedprotein-kinase (MAPK) pro-survival signaling pathway members (e.g. AKT and ERK) relative to wild-type HER2 18 . To determine whether HER2 V659E constitutively activates downstream signaling in cPAC, we first validated HER2 genotype in seven canine lung cancer cell lines through amplicon sequencing, ddPCR or Sanger sequencing of the V659 locus, Sanger sequencing of all HER2 coding regions, and/or aCGH to determine HER2 copy number status as previously published 19 (Table S10) . One cell line, OSUK9PAPADOscar, bore a low allele frequency HER2 V659E mutation when sequenced by amplicon panel at low passage (passage 4) as a primary culture, but had lost this allele in later established passages (passage 15) characterized by Sanger sequencing and ddPCR and utilized for functional studies. We thus evaluated HER2 activation in one HER2 V659E cPAC cell line, OSUK9PAPADRex, and three HER2 WT cell lines (two cPAC -CLAC and OSUK9PAPAPADOscar -and one cPASC -OSUK9PADSQ) by
Western blotting for total and phospho-AKT in the presence and absence of the ErbB ligand, neuregulin (hNRG) post-serum starvation. Only the HER2 V659E line, OSUK9PAPADRex, showed constitutively high AKT phosphorylation post-starvation even in the absence of hNRG stimulation (Figure 2A) .
HER2 V659E cPAC cell lines are selectively sensitive to HER2 inhibitors
HER2 V659E has been shown to stabilize receptor dimerization and constitutively activate downstream pro-survival signaling 20 . Therefore, anti-HER2 drugs may prove effective for selectively eradicating HER2 V659E tumors. We evaluated differential sensitivity of HER2 V659E and HER2 WT canine lung cancer cell lines to the small molecule HER2 inhibitors lapatinib and neratinib. Five cPAC cell lines (two HER2 V659E and three HER2 WT ) and two HER2-mutant human cancer cell lines -BT474 (HER2 AMP ) and H1781 (kinase domain HER2 G776ins ), both of which are known to respond to HER2 inhibitors 18,21 -were treated with neratinib and four (one HER2 V659E and three HER2 WT ) with lapatinib for 72 hours (Figures 2B and S6 ). Significant differences in viability were observed between HER2 V659E and HER2 WT cPAC cell lines for both drugs with IC 50 s < 200 nM in HER2 V659E versus IC 50 s > 2500 nM in HER2 WT . All HER2-mutant cell lines were sensitive to neratinib with IC 50 s < 50 nM (Figure 2B ) significantly lower than HER2 WT responses (p=0.0079). We additionally observed a neratinib dose-dependent decrease in p-AKT in the HER2-mutant cell lines OSUK9PAPADRiley (HER2 V659E ) and BT474 (HER2 amp ) whereas p-AKT levels in OSUK9PAPADOscar (HER2 WT ) were low at all treatment levels ( Figure 2C) . These studies further support that HER2 V659E in cPAC is an activating event that confers dependency on downstream signaling and sensitivity to targeted HER2 inhibition.
DISCUSSION
Through multi-platform next-generation sequencing of 88 naturally occurring primary canine NSCLC cases (77 tumors and 11 cell lines), we describe for the first time the detailed genomic underpinnings of this cancer. The cohort included major NSCLC subtypes occurring in dogs and humans: cPAC (n=74, cPASC (n=11), and cPSCC (n=3) (Table S1, Figure S1 ). Although lung cancer may be over-represented in Doberman pinschers, Australian shepherds, Irish setters, and Bernese mountain dogs 7 , Labrador retrievers comprised the largest pure breed in this cohort (21%) followed by mixed breeds (25%) and multiple other pure breeds in smaller numbers. The cohort was gender-balanced (52% females), primarily neutered/spayed (92%), and bore a median age at diagnosis of 11 years. Although second-hand smoke exposure in these dogs remains possible given that exposure was not recorded, genomic landscapes of human lung cancers in never-smokers have not been shown to differ based on exposure to second-hand smoke 22 .
Exposure to other environmental carcinogens such as air pollutants may also play a role in development of lung cancers. For example, increased lung cancer risk may be present in dogs with higher amounts of carbon deposits known as anthracosis 23 , although in humans anthracosis has been commonly observed in normal lungs as well as tumors and lymph nodes. A mutational etiology for such pollutant exposure has also not been established. In this cohort, anthracosis was recorded in 15 cases and pneumoconiosis (lung disease associated with pollutant exposure) in one case. However, no associations between anthracosis annotation and genetic features of these cases were observed. Overall, our studies included broad representation of lung cancer across histologic subtypes, breeds, ages, and pollutant exposures reflective of primary canine lung cancer diversity seen in the clinical setting in the United States.
Unique genomic characteristics of human never-smoker lung cancer include low somatic mutation burden, C:G>T:A enrichment, and activating mutations or fusions impacting EGFR (45%), ALK (5-11%), ROS (1.5-6%), HER2 (3-5%), and RET (2%) 4, 24 . Here, we also observed a low somatic burden of SNVs, CNVs, and SVs through exome sequencing in five matched tumor/normal cPAC pairs. We additionally observed that the most common mutation signature in these five cases was the age-associated COSMIC Signature 1A in 4/5 (80%) featuring frequent C>T substitutions at NpCpG trinucleotides and similar to the C>T substitution enrichment seen in human NSCLC (Figure S3 ). This signature is associated with age in many human cancers, putatively the result of spontaneous deamination of 5-methyl-cytosine. COSMIC Signature 2, associated with APOBEC cytidine deaminase activity, was also present in two cases. This signature, characterized by C>T and C>G substitutions at TpCpN, is most prominently associated with cervical and bladder cancers, but is also commonly found in 16 cancer types including lung adenocarcinoma and squamous cell carcinoma. While these signatures are sometimes associated with APOBEC gene variants in human cancers 25 , no putatively pathogenic germline or somatic APOBEC mutations were observed. Based on our studies, primary canine lung cancers bear a low mutation burden and mutation signatures reflective of those seen in human never-smoker lung cancers.
The most common recurrently mutated genes containing somatic potentially pathogenic SNVs in the full cohort included HER2 (31.5%), TP53 (12.5%), PTEN (5.7%), SMAD4 (4.5%), KRAS (4.5%), VHL (3.4%) and HRAS (2.3%). Recurrent CDKN2A/B focal deletions were also observed in 2/5 (40%) cases (Figure 1A, 1B) . While HER2 contained the largest number of somatic mutations identified in this study, the broader driver mutation landscape provides an informative view of the genetic underpinnings of primary canine lung cancer. CDKN2A deletions were the most common alteration by frequency overall, occurring at rates comparable to those in human NSCLC. Two focal deletions were observed out of five exome-sequenced cases with signs of larger-scale CFA11 losses in remaining cases (Figure S2) . We additionally identified a single case bearing a homozygous missense mutation, G50R, equivalent to codon G101 mutations in human cancer (14 reports according to COSMIC). CDKN2A is mutated in ~30% of all human NSCLC, primarily via homozygous deletion, and this number is reduced to around 25% in neversmokers. The next most common alterations after CDKN2A and HER2 were TP53 missense and truncating mutations comparable to DNA binding domain mutations in human TP53. Similar to human NSCLC, we observed a reduced burden of TP53 mutations (12.4%) relative to human smoker NSCLC in which more than half of tumors are mutated. We found two stop gains and nine missense mutations. Notable likely pathogenic missense mutations with human equivalents include R164H (human R175, 1,857 mutations in COSMIC), R239Q/G (human R249, 739 mutations in COSMIC), and R272H (human R282, 955 mutations in COSMIC).
PTEN mutations were the next most common alterations at 5.6%. PTEN is mutated in ~9% of human NSCLC, but only ~2% of never-smoker NSCLC. In addition to a homozygous deletion in a single exome-sequenced case, PTEN mutations were predominantly stop gains in three of five cases bearing somatic SNVs. The remaining two PTEN mutations were missense, occurring in the C2 domain and included D230Y (comparable to human pathogenic D252Y) and C228R (no comparable human variant). We additionally identified four somatic mutations in the tumor suppressor SMAD4, mutated in ~5% of human NSCLC at comparable rates in smoker and neversmoker cancer. These mutations included three D351 codon mutations and W524C, all in the MH2 domain, comparable to those recurrently described in human lung cancer. The SMAD4 protein shares 99% identity between dog and human with D351 being the 4 th most commonly mutated codon (45 mutations in human lung cancer from COSMIC).
KRAS mutations are the most common oncogenic mutations in human smoker NSCLC (~30-40% of cases), but occur at reduced frequencies in never-smoker lung cancer (0-7%). We observed a low frequency of KRAS mutations. The KRAS protein shares 100% identity between dog and human with the G12 codon in the nucleotide binding domain being the most commonly mutated region. KRAS mutations in our cohort (2 G12V, 1 G12D, and 1 Q61K) were comparable to human hotspots in codons G12 and Q61. Missense mutations in canine HRAS were also located in human-equivalent hotspots (Q61L, F78S). Additional likely pathogenic somatic mutations included individual cases of AKT1 amplification, KIT/KDR amplification, EGFR A726T (human A755), MET M1269V (human M1268), and VHL P97L (human P97). WWTR1, the only COSMIC gene bearing a somatic translocation in exome-sequenced cases, has been shown to undergo translocation with CAMTA1 in human epithelioid hemangioendothelioma 26 . Here, we identified a WWTR1 translocation of unknown consequence with ATP5F1. Overall, although we observed a similar mutation spectrum relative to human never-smoker NSCLC, a notable exception is lack of EGFR mutations which, although present in few smoker lung cancers (0-7%), are enriched in human never-smokers (~45%). Further, although we identified translocations occurring in coding regions in five exome-sequenced tumors, it remains possible that, as in human never-smoker lung cancer, EML4-ALK fusions, ROS1 fusions, RET fusions, and other fusions may be present in canine lung cancer.
In addition to charting the landscape of cPAC, we have found recurrent KRAS and TP53 mutations in cPASC and provide a view of possible drivers in cPSCC. In cPASC, HRAS Q61L and KRAS Q61K each occurred in one case (18% of cases thus with RAS mutations. Finally, while no recurrent mutations were identified in the three cPSCCs, we identified one case with somatic BRAF V588E (equivalent to the human V600E hotspot) and another bearing PTPN11 G503V (equivalent to the human G503V hotspot).
HER2 contained the largest number of somatic mutations with high frequency hotspot mutations occurring solely in cPAC (37.8%). HER2 is a well-characterized human oncogene and drug target mutated in ~6% of all cancers based on cBioPortal query of 10,967 cases in the TCGA pan-cancer atlas 27, 28 . The majority of these alterations are focal amplifications, but activating point mutations are also common. In human NSCLC, HER2 mutations have been identified as oncogenic drivers in ~1-4% of cases, mostly in exon 20 at codon 776 resulting in constitutive HER2 kinase domain activation and downstream signaling through PI3K and MAPK pathways 24, 29, 30 . It may also be more commonly mutated in human never-smoker lung cancer, with point mutations at frequencies of 3-5% 31 . HER2-mutant human NSCLC is predominately female never-smokers with adenocarcinomas who carry a median OS of ~2 years 30 . HER2 TMD polar mutations (HER2 V659E/D , HER2 G660D ) such as those we have discovered in cPAC are present in 0.18% of human lung adenocarcinomas and are exclusive with HER2 kinase domain mutations 32 . We determined HER2 status in canine lung cancer through multi-platform analysis.
Our amplicon analysis covered canine HER2 exons 8 and 17-22 including transmembrane and kinase domains. Additionally, we performed Sanger sequencing of all exons in five canine cell lines with wild-type HER2 based on amplicon sequencing (OSUK9PAD, BACA, CLAC, K9PADSQ and OSULSCC1) and found no somatic HER2 mutations in other sites (Table S10) .
It is nonetheless possible that somatic mutations occurring in other regions of HER2 were not identified in amplicon-sequenced samples even though data facilitating functional interpretation of these variants would be limited.
In addition to point mutations, HER2 amplification has also been identified in ~1% of human NSCLC 24 , with enrichment in EGFR-inhibitor-resistant tumors 33 . Protein overexpression has been reported in 6-35% of tumors including up to 42% of adenocarcinomas and has been shown to correlate with poor prognosis [34] [35] [36] [37] . We detected no somatic HER2 focal amplifications or largescale CFA9 gains in five exome-sequenced cases (Figure 1B and S2) or two previously aCGH-profiled cell lines. However, four of these seven cases contained somatic, putatively activating HER2 SNVs. Given that HER2 amplification/overexpression and SNVs are typically mutually exclusive, it remains possible that our broader amplicon cohort contained undetected HER2 amplifications. We therefore utilized qRT-PCR and IHC studies to more broadly assess HER2 overexpression and did not find evidence for significant tumor-specific HER2 overexpression ( Figures S4 and S6 and Table S12 ). Thus, it is unlikely that HER2 is frequently amplified in primary canine lung cancer. Rather, point mutation appears to be the primary mechanism of HER2 hyperactivation.
We have additionally shown that HER2 hotspot mutations can be detected in the plasma of dogs bearing HER2 V659E cPACs even at early stages of the disease (at least stage II) ( Figure 1E and Table S11 ). In human NSCLC, ctDNA has been shown to be significantly enriched in plasma relative to controls with key genetic features identifiable via liquid biopsy. Associations have been found between ctDNA levels and tumor stage, grade, lymph node status, metastatic sites, response, and survival 38, 39 . In fact, the first FDA-approved liquid biopsy test for lung cancer was the cobas EGFR Mutation Test v2, a real-time PCR assay utilized in NSCLC for the detection of EGFR exon 18-21 mutations in tissue or plasma to guide EGFR inhibitor treatment assignment 40, 41 . Our proof-of-principle study supports that ctDNA is also detectable in primary canine lung cancer patient plasma. A non-invasive HER2 V659E assay will enable genotyping patients when tumor tissue is limited and may have a role in treatment monitoring or detection of minimal residual disease. This assay will also facilitate prospective analysis of HER2 V659E 's diagnostic and prognostic value.
Canine HER2 shares normal and oncogenic roles with human HER2 based on sequence conservation and prior study of its role in cell signaling in the dog. It shares 92.2% amino acid identity with human HER2. HER2 V659E occurs at a highly conserved residue identical to the human variant (100% identity with human HER2 in the TMD from amino acids 654-674) and to the neu (rat HER2) variant identified in a rat glioblastoma cell line that originally led to discovery of HER2's oncogene status 42 . HER2 has been implicated in canine cancers via overexpression by IHC and qRT-PCR in canine mammary tumors 43 , through its utility as a vaccine target in canine osteosarcoma 44 , and through downstream signaling hyperactivation in canine lung cancer 10 . In human cancers, HER2 TMD polar mutations like those discovered here, have been shown to constitutively activate pro-survival HER2 signaling 32 and have been associated with responses to HER2 inhibitors 20 . We have confirmed in this study that, similar to human HER2 TMD mutants, canine HER2 V659E cell lines constitutively activate downstream signaling through AKT and are selectively sensitive to HER2 inhibitors in vitro including lapatinib and neratinib (Figure 2 and S6) .
We have charted the genomic landscape of primary canine lung cancers including the NSCLC subtypes cPAC, cPASC, and cPSCC. We have identified recurrent HER2 mutations in these cancers and present, to our knowledge, the first complete suite of evidence supporting an oncogenic role for and dependency on constitutively activating mutations in HER2 in a canine cancer. Further work is needed to more comprehensively profile these tumors, particularly according to variation across breeds, and to determine the prognostic significance of the mutations described here. However, these data offer immediate diagnostic and therapeutic opportunities for dogs with primary lung cancer. They aid comparative understanding of neversmoker and HER2-mutant lung cancer across species.
ONLINE METHODS
Sample Collection
Tumors and cell lines from 89 dogs from the Canine Comparative Oncology and Genomics Consortium (CCOGC) 45 
Exome Sequencing and Analysis
Informatic tools, versions, and flags are shown in Table S13 . We utilized a custom Agilent SureSelect canine exome capture kit with 982,789 probes covering 19,459 genes. Exome libraries were sequenced on the Illumina HiSeq2000 producing paired end reads of 85bp. 
Targeted Amplicon Sequencing and Analysis
We developed a custom canine cancer amplicon sequencing panel consisting of 281 amplicons targeting exons and hotspot regions in 57 genes, with amplicon sizes ranging from 91-271 bp (Table S6 ). We pooled primers in two multiplexed pools to separate adjacent amplicons and any amplicons that showed cross-amplification using in silico PCR. We prepared sequencing libraries using digital PCR amplification following the manufacturer's protocols for the ThunderBolts Cancer Panel (RainDance Technologies) with modifications as previously described 46 . Sequencing was performed on the Illumina MiSeq generating paired-end 275 bp reads. Sequencing reads were demultiplexed and extracted using Picardtools. Sequencing adapters were trimmed using ea-utils and fastq files were assessed for quality using FASTQC.
Sequencing reads were aligned to CanFam3.1 using bwamem-MEM 47 . Custom in-house scripts based on samtools were used to create pileups for every sample. Pileups were analyzed in R to call SNVs and indels. For each potential non-reference allele at each targeted locus in a sample, we evaluated the distribution of background noise across all other sequenced samples. To call a variant, we required the observed non-reference allele is an outlier from the background distribution with a Z-score > 5. In addition, we required tumor depth 
HER2 Inhibitor Drug Dose-Response Studies
HER2 inhibitors lapatinib (Selleckchem, #S2111) and neratinib (Puma Biotechnology, Los Angeles, CA), were assessed in 10-16 point 72 hr drug-dose response screens (from 2x10 -7 nM to 100 µM) with CellTiter-Glo ® luminescent cell viability assay (Promega, #G7570). Cells were cultured in RPMI supplemented with 10% FBS and 1% Penicillin/Streptomycin. Luminescence was read using Synergy Mx (Biotek) plate reader. Six replicates were performed for each dose.
Curve-fitting and IC 50 calculations were performed using GraphPad Prism v7.00 (GraphPad Software, La Jolla, CA). 48 . Negative controls were performed on all tissues using a universal rabbit negative isotype control not directed against any known antigen (Dako, #IR600).
Droplet Digital PCR
Quantitative Image Analysis
Immunostained and control 1x3-inch microscope slides were scanned at 40X on a high- Table S1 . Extended clinical and multiplatform annotation of primary canine lung cancer cases. Table S2 . Sequencing metrics for primary canine lung cancer exome analysis. 
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